202 Magazine October 2013 October 2013 | Page 26

/ 202 SPOTLIGHT / Battling breast cancer on two fronts Local scientist studies cancer in the lab, supports survivors around the Valley by Kimberly Hosey O ne might think that dedicating your life to one cancer-fighting mission is doing enough for breast cancer survivors and victims. Bodour Salhia doesn’t think so. She supports breast cancer research from both “sides,” joining in fundraising efforts like the Susan G. Komen Race for the Cure – and doing the actual research in the lab. Salhia is a researcher from Chandler working at the Translational Genomics Institute in Phoenix, where she studies genomics, cancer, molecular biology and personalized medicine. As a scientist, communicator and patient advocate; Salhia is intimately familiar with the problem of cancer in 26 the general sense as well as in the difficult specifics, and she shares that expertise with cancer survivors in the Valley. Salhia studies what makes breast cancer metastasize – or spread – to other organs, such as the brain or bones. Salhia’s area of research, genomics, focuses on the genetic material of a cell and how it develops, functions or can mutate to trigger cancer. “Once a patient develops metastatic breast cancer, the survival really plummets,” Salhia says. She’s optimistic, however, that “being able to predict metastasis very very early on might eventually lead to preventative measures” that might save people from the spread of cancer. 202 magazine / october 2013 / 202magazine.com Salhia is hopeful that as the many diverse factors affecting the development of cancer become better understood, new therapies can be developed and tested, eventually leading to personalized medicine that treats each person on an individual level to eliminate the root causes of cancer. The research is abstract, extremely detailed and brings together many different areas of expertise (all strongly represented at TGEN) to bear on the problem of cancer. Genomics might be foreign to most, but the idea of coming together to tackle the intimidating and ever-morphing problem of cancer should sound familiar to many cancer survivors.